Neuroendocrine cancer

Neuroendocrine cancer (also known as NETs) is a cancer type that arises from cells of the neuroendocrine system (cells that release hormones in our body). They are classified according to where the primary tumour originated from, and the most common types are gastrointestinal, lung or pancreatic NETs.


Latest Research and Reviews

News and Comment

  • News & Views |

    In two phase III trials, surufatinib, a novel oral tyrosine kinase inhibitor targeting immune cells and angiogenesis, was effective for treating pancreatic and extra-pancreatic neuroendocrine tumours. These findings further expand the therapeutic options for patients with gastro–entero–pancreatic, thymic and lung neuroendocrine tumours.

    • Anna Koumarianou
    •  & Gregory Kaltsas
  • Comments & Opinion |

    The first International Symposium on Phaeochromocytoma in 2005 was followed by considerable progress in the field, largely owing to the many collaborations and networks stimulated by that and subsequent meetings. The rich hereditary background of phaeochromocytomas has since provided for strong interdisciplinary links of genetics with personalized diagnostics, imaging and therapeutic interventions.

    • Karel Pacak
    • , Graeme Eisenhofer
    •  & Arthur S. Tischler
  • News & Views |

    Neuroendocrine liver metastases often require multiple modes of treatment to attain disease control, which can utilize various forms of radiolabelled agents either delivered systemically or preferentially towards the liver. A recent trial suggested both safety and efficacy of a novel approach of combining the two to provide a radiation ‘boost’ to hepatic deposits.

    • Andrea Frilling
    •  & Ashley Kieran Clift
  • Comments & Opinion |

    Studies uncovering the cellular mechanisms of adaptation to varying oxygen levels were recognized with the 2019 Nobel Prize in Physiology or Medicine. Here, we focus on the remarkable parallels between the pathways regulating oxygen availability and those driving rare neuroendocrine tumours, phaeochromocytomas and paragangliomas, and discuss the translational implications of this connection.

    • Patricia L. M. Dahia
    •  & Rodrigo A. Toledo
  • Correspondence |

    • Mariano J. Alvarez
    • , Pengrong Yan
    • , Mary L. Alpaugh
    • , Michaela Bowden
    • , Ewa Sicinska
    • , Chensheng W. Zhou
    • , Charles Karan
    • , Ronald B. Realubit
    • , Prabhjot S. Mundi
    • , Adina Grunn
    • , Dirk Jäger
    • , John A. Chabot
    • , Antonio T. Fojo
    • , Paul E. Oberstein
    • , Hanina Hibshoosh
    • , Jeffrey W. Milsom
    • , Matthew H. Kulke
    • , Massimo Loda
    • , Gabriela Chiosis
    • , Diane L. Reidy-Lagunes
    •  & Andrea Califano
    Nature Genetics 51, 1427-1428